Abstract
Background
Previous investigations assessing the genetic cause of pediatric hypertrophic cardiomyopathy (HCM) found underlying genetic mutations in 50–60% of cases. The purpose of our study was to analyze whether this number can be augmented by applying next-generation sequencing and directing further diagnostics by discussing unsolved cases in a multidisciplinary board.
Methods and results
42 patients with the diagnoses of HCM made before age 18 years were treated in our center from 2000 to 2016. Genetic analysis was performed in 36 subjects, a genetic defect was detected in 29 (78%) patients. 15 individuals (42%) had pathogenic variants in genes encoding sarcomere proteins, and 5 (14%) in genes coding for components of the RAS/MAPK signaling pathway. 4 subjects (11%) had mutations in the GAA gene (Pompe disease), and 3 (8%) had Frataxin repeat expansions (Friedreich’s ataxia). One patient each showed a mutation in BAG3 and LMNA. Discussion of unsolved HCM cases after performing next-generation sequencing (28 genes) in an interdisciplinary board unraveled the genetic cause in 9 subjects (25%).
Conclusion
A definite genetic diagnosis can be reached in nearly 80% with HCM of childhood onset. Next-generation sequencing in conjunction with a multidisciplinary cooperation can enhance the diagnostic yield substantially. This may be important for risk stratification, treatment planning and genetic counseling.
Similar content being viewed by others
References
Bharucha T, Lee KJ, Daubeney PE, Nugent AW, Turner C, Sholler GF, Robertson T, Justo R, Ramsay J, Carlin JB, Colan SD, King I, Weintraub RG, Davis AM, Investigators N (2015) Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. J Am Coll Cardiol 65:2302–2310. https://doi.org/10.1016/j.jacc.2015.03.552
Burghardt A, van Buuren F, Dimitriadis Z, Grubbel T, Seggewiss H, Scholtz S, Horstkotte D, Faber L (2018) Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 107:479–486. https://doi.org/10.1007/s00392-018-1209-3
Chaowu Y, Shihua Z, Jian L, Li L, Wei F (2013) Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy. Circ Heart Fail 6:1013–1020. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000414
Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 115:773–781. https://doi.org/10.1161/CIRCULATIONAHA.106.621185
Dinshaw L, Munch J, Dickow J, Lezius S, Willems S, Hoffmann BA, Patten M (2018) The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy. Clin Res Cardiol 107:130–137. https://doi.org/10.1007/s00392-017-1164-4
Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE (2010) Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation 122:1130–1133. https://doi.org/10.1161/CIRCULATIONAHA.110.950089
Gelb BD, Tartaglia M (2011) RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it. J Clin Investig 121:844–847. https://doi.org/10.1172/JCI46399
Hahn A, Lauriol J, Thul J, Behnke-Hall K, Logeswaran T, Schanzer A, Bogurcu N, Garvalov BK, Zenker M, Gelb BD, von Gerlach S, Kandolf R, Kontaridis MI, Schranz D (2015) Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog. Am J Med Genet Part A 167A:744–751. https://doi.org/10.1002/ajmg.a.36982
Hickey EJ, McCrindle BW, Larsen SH, Benson L, Manlhiot C, Caldarone CA, Van Arsdell GS, McCrindle BM, Williams WG (2012) Hypertrophic cardiomyopathy in childhood: disease natural history, impact of obstruction, and its influence on survival. Ann Thoracic Surg 93:840–848. https://doi.org/10.1016/j.athoracsur.2011.10.032
Kearney M, Orrell RW, Fahey M, Brassington R, Pandolfo M (2016) Pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007791.pub4
Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM, Sleeper LA, Cox GF, Hsu DT, Canter CE, Hunter JA, Colan SD, Pediatric Cardiomyopathy Registry Study G (2013) Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 382:1889–1897. https://doi.org/10.1016/S0140-6736(13)61685-2
Lopes LR, Zekavati A, Syrris P, Hubank M, Giambartolomei C, Dalageorgou C, Jenkins S, McKenna W,, Plagnol V, Elliott PM (2013) Uk10k C. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 50:228–239. https://doi.org/10.1136/jmedgenet-2012-101270
Marian A (2008) Utilities and limitations of genetic testing for hypertropic cardiomyopathy. Expert Opin Med Diagn 2:539–546. https://doi.org/10.1517/17530059.2.5.539
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (Young) Adults. Circulation 92:785–789
Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, Towbin JA, Seidman JG, Seidman CE (2008) Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 358:1899–1908. https://doi.org/10.1056/NEJMoa075463
Nugent AW, Daubeney PE, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG, National Australian Childhood Cardiomyopathy S (2005) Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 112:1332–1338. https://doi.org/10.1161/CIRCULATIONAHA.104.530303
Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M, Project EHF (2003) Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107:2227–2232. https://doi.org/10.1161/01.CIR.0000066323.15244.54
Rubattu S, Bozzao C, Pennacchini E, Pagannone E, Musumeci BM, Piane M, Germani A, Savio C, Francia P, Volpe M, Autore C, Chessa L (2016) A next-generation sequencing approach to identify gene mutations in early- and late-onset hypertrophic cardiomyopathy patients of an italian cohort. Int J Mol Sci. https://doi.org/10.3390/ijms17081239
Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, Proctor T, Ehlermann P, Jensen K, Katus HA, Meder B (2018) Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 107:30–41. https://doi.org/10.1007/s00392-017-1155-5
Ullal AJ, Abdelfattah RS, Ashley EA, Froelicher VF (2016) Hypertrophic cardiomyopathy as a cause of sudden cardiac death in the young: a meta-analysis. Am J Med 129:486–496 e482. https://doi.org/10.1016/j.amjmed.2015.12.027
Windram JD, Benson LN, Dragelescu A, Yoo SJ, Mertens L, Wong D, Grosse-Wortmann L (2015) Distribution of hypertrophy and late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy. Congenit Heart Dis 10:E258–E267. https://doi.org/10.1111/chd.12286
Ziolkowska L, Turska-Kmiec A, Petryka J, Kawalec W (2016) Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatric cardiology 37:448–458. https://doi.org/10.1007/s00246-015-1298-y
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Rupp, S., Felimban, M., Schänzer, A. et al. Genetic basis of hypertrophic cardiomyopathy in children. Clin Res Cardiol 108, 282–289 (2019). https://doi.org/10.1007/s00392-018-1354-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-018-1354-8